Theramex Announces Agreement to Acquire the European Rights to Duphaston® and Femoston® From Viatris, Inc.
“As we continue to strengthen our commitment to women’s health and improve our patients access to high quality treatments, we are excited to acquire new products to expand our Menopause portfolio.” - Rob Stewart, CEO of Theramex.
Duphaston® (dydrogesterone) and Femoston® (estradiol/dydrogesterone) may be prescribed in indications related to hormone replacement therapy (HRT).
About Theramex
Theramex is a leading, global specialty pharmaceutical company dedicated to women and their health. With a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis, Theramex supports women at different stages of their lives. Our vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing innovative, effective solutions that care for and support women as they advance through each stage of their lives. To learn more about Theramex, please visit www.theramex.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231002698068/en/
Website: https://www.theramex.com/
Contact
Theramex
Katja Lundell
Senior Director, Global Head of Policy, Pricing and Communications.
THX_HQ_PRESSR_011393
+44 203 962 5555
Katja.Lundell@theramex.com
This news is a press release provided by Theramex. Korea Newswire follows these editorial guidelines.
-
2022년 2월 9일 16:15